ARTICLE | Company News
Valentis, Prolong PEG licensing deal
February 10, 2003 8:00 AM UTC
Valentis (VLTSD) licensed its OptiPEG PEGylation technology to biogenerics company Prolong Pharmaceuticals (Califon, N.J.) to develop and market PEGylated protein therapeutics. Prolong will develop, m...